1
|
Bonnett S, Jee JA, Chettiar S, Ovechkina Y, Korkegian A, Greve E, Odingo J, Parish T. Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis. Microbiol Spectr 2023; 11:e0497422. [PMID: 36688635 PMCID: PMC9927457 DOI: 10.1128/spectrum.04974-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 12/19/2022] [Indexed: 01/24/2023] Open
Abstract
We identified an amino-benzothiazole scaffold from a whole-cell screen against recombinant Mycobacterium tuberculosis under expressing the essential signal peptidase LepB. The seed molecule had 2-fold higher activity against the LepB hypomorph. Through a combination of purchase and chemical synthesis, we explored the structure-activity relationship for this series; 34 analogs were tested for antitubercular activity and for cytotoxicity against eukaryotic cells. We identified molecules with improved potency and reduced cytotoxicity. However, molecules did not appear to target LepB directly and did not inhibit protein secretion. Key compounds showed good permeability, low protein binding, and lack of CYP inhibition, but metabolic stability was poor with short half-lives. The seed molecule showed good bactericidal activity against both replicating and nonreplicating bacteria, as well as potency against intracellular M. tuberculosis in murine macrophages. Overall, the microbiological properties of the series are attractive if metabolic stability can be improved, and identification of the target could assist in the development of this series. IMPORTANCE Mycobacterium tuberculosis, the causative agent of tuberculosis, is a serious global health problem requiring the development of new therapeutics. We previously ran a high-throughput screen and identified a series of compounds with antitubercular activity. In this paper, we test analogs of our hit molecules for activity against M. tuberculosis, as well as for activity against eukaryotic cells. We identified molecules with improved selectivity. Our molecules killed both replicating and nonreplicating bacteria but did not work by targeting protein secretion.
Collapse
Affiliation(s)
- Shilah Bonnett
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Jo-Ann Jee
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Somsundaram Chettiar
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Yulia Ovechkina
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Aaron Korkegian
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Eric Greve
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA
| | - Joshua Odingo
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
| | - Tanya Parish
- TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA
| |
Collapse
|
2
|
McNeil MB, Chettiar S, Awasthi D, Parish T. Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis. Access Microbiol 2019; 1:e000006. [PMID: 32974492 PMCID: PMC7470358 DOI: 10.1099/acmi.0.000006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 01/16/2019] [Indexed: 11/18/2022] Open
Abstract
There is a need for new combination regimens for tuberculosis. Identifying synergistic drug combinations can avoid toxic side effects and reduce treatment times. Using a fluorescent rifampicin conjugate, we demonstrated that synergy between cell wall inhibitors and rifampicin was associated with increased accumulation of rifampicin. Increased accumulation was also associated with increased cellular permeability.
Collapse
Affiliation(s)
- Matthew B McNeil
- TB Discovery Research, Infectious Disease Research Institute, Seattle, WA, USA.,Present address: Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
| | | | - Divya Awasthi
- TB Discovery Research, Infectious Disease Research Institute, Seattle, WA, USA
| | - Tanya Parish
- TB Discovery Research, Infectious Disease Research Institute, Seattle, WA, USA
| |
Collapse
|
3
|
Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O’Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T. Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB. ACS Infect Dis 2017; 3:898-916. [PMID: 29035551 PMCID: PMC5727484 DOI: 10.1021/acsinfecdis.7b00112] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
![]()
The phenoxy alkyl benzimidazoles
(PABs) have good antitubercular activity. We expanded our structure–activity
relationship studies to determine the core components of PABs required
for activity. The most potent compounds had minimum inhibitory concentrations
against Mycobacterium tuberculosis in the low nanomolar
range with very little cytotoxicity against eukaryotic cells as well
as activity against intracellular bacteria. We isolated resistant
mutants against PAB compounds, which had mutations in either Rv1339,
of unknown function, or qcrB, a component of the
cytochrome bc1 oxidase of the electron
transport chain. QcrB mutant strains were resistant to all PAB compounds,
whereas Rv1339 mutant strains were only resistant to a subset, suggesting
that QcrB is the target. The discovery of the target for PAB compounds
will allow for the improved design of novel compounds to target intracellular M. tuberculosis.
Collapse
Affiliation(s)
- N. Susantha Chandrasekera
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Bryan J. Berube
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Gauri Shetye
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Somsundaram Chettiar
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Theresa O’Malley
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Alyssa Manning
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Lindsay Flint
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Divya Awasthi
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | | | | | - Thierry Masquelin
- Lilly Research Laboratories, 307 East Merrill Street, Indianapolis, Indiana 46285, United States
| | - Philip A. Hipskind
- Lilly Research Laboratories, 307 East Merrill Street, Indianapolis, Indiana 46285, United States
| | - Joshua Odingo
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| | - Tanya Parish
- TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Seattle, Washington 98102, United States
| |
Collapse
|
4
|
Tang Z, Acuña UM, Fernandes NF, Chettiar S, Li PK, DE Blanco EC. Structure-Activity Relationship of Niclosamide Derivatives. Anticancer Res 2017; 37:2839-2843. [PMID: 28551619 DOI: 10.21873/anticanres.11635] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 04/26/2017] [Accepted: 04/28/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Cancer is a leading cause of death. Hence, this study aimed at the optimization of niclosamide derivatives for the development of new potential anticancer agents. MATERIALS AND METHODS Niclosamide derivatives were synthesized and tested against a panel of human cancer cells: MDA and MCF7 breast cancer cells, PC3 and DU-145 prostate cancer cells, Hela cervical cancer cells, and HL-60 acute promyelocytic leukemia cells. They were also tested in nuclear factor-ĸappa B (NFĸB), V-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and mitochondria transmembrane potential (MTP) assays. RESULTS N-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide exhibited the most significant cytotoxicity against HL-60 cells, while 5-chloro-N-(2-chlorophenyl)-2-hydroxybenzamide was the most active in the NFĸB assay and 5-chloro-N-(3,5-difluorophenyl)-2-hydroxybenzamide in the MTP assay. 5-chloro-N-(2-chloro-4-(trifluoromethyl) phenyl)-2-hydroxybenzamide and 5-chloro-2-hydroxy-N-(4-hydroxyphenyl)benzamide inhibited both HL-60 cell proliferation and NFĸB. CONCLUSION In-depth study of the most promising compounds is highly encouraged to further develop into potential anticancer agents those derivatives found to be significantly active.
Collapse
Affiliation(s)
- Zhonghai Tang
- Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.,Department of Food Quality and Safety, College of Food Science and Technology,
Hunan Agricultural University, Changsha, P.R. China
| | - Ulyana Muñoz Acuña
- Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.,Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A
| | - Nelson Freitas Fernandes
- Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.,Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A
| | - Somsundaram Chettiar
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A
| | - Pui-Kai Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A
| | - Esperanza Carcache DE Blanco
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.,Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A.
| |
Collapse
|
5
|
Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer. Bioorg Med Chem 2017; 25:2156-2166. [PMID: 28259529 DOI: 10.1016/j.bmc.2017.02.030] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 02/10/2017] [Accepted: 02/12/2017] [Indexed: 11/24/2022]
Abstract
New targeted therapy approaches for certain subtypes of breast cancer, such as triple-negative breast cancers and other aggressive phenotypes, are desired. High levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC). Novel small molecules targeting Mps1 were designed by computer assisted docking analyses, and several candidate compounds were synthesized. These compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions. The results indicate that the lead compounds have strong anti-proliferative potential through Mps1/TTK inhibition in both basal and luminal BC cell lines, exhibiting IC50 values ranging from 0.05 to 1.0μM. In addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356μM to 0.809μM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells. The most promising analog, compound 13, significantly decreased tumor growth in nude mice containing Cal-51 triple negative breast cancer cell xenografts. Using drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.
Collapse
Affiliation(s)
- Yasuro Sugimoto
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Dwitiya B Sawant
- Department of Molecular Genetics, College of Arts & Sciences, The Ohio State University, Columbus, OH 43210, USA
| | - Harold A Fisk
- Department of Molecular Genetics, College of Arts & Sciences, The Ohio State University, Columbus, OH 43210, USA
| | - Liguang Mao
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Chenglong Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Somsundaram Chettiar
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Pui-Kai Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Michael V Darby
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
| | - Robert W Brueggemeier
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
| |
Collapse
|
6
|
Affiliation(s)
- Anuradha Kumar
- TB Discovery Research, Infectious Disease Research Institute, Seattle, WA, USA
| | | | - Tanya Parish
- TB Discovery Research, Infectious Disease Research Institute, Seattle, WA, USA
| |
Collapse
|
7
|
Tran P, Gajula R, Williams R, Malek R, Nugent K, Walker A, Chettiar S, Wang H, Taparra K, Cades J, Herman J. A Twist1-MLL-WDR5-HOTTIP Complex Regulates HOXA9 Chromatin to Facilitate Metastasis of Prostate Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.691] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Tran P, Bellovin D, Adam S, Gentles A, Roessler S, Thiyagarajan S, Aziz K, Chettiar S, Luong R, Plevritis S. Twist1 Induces the Step-Wise Malignant Progression of Liver Cancer in Transgenic Mice Revealing a Prognostic 19-Gene Signature for Humans. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res 2013; 73:5288-98. [PMID: 23824741 DOI: 10.1158/0008-5472.can-13-0874] [Citation(s) in RCA: 129] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Interleukin (IL)-6 overexpression and constitutive STAT3 activation occur in many cancers, including prostate cancer. However, their contribution to prostate stem and progenitor cells has not been explored. In this study, we show that stem-like cells from patients with prostate cancer secrete higher levels of IL-6 than their counterparts in non-neoplastic prostate. Tumor grade did not influence the levels of expression or secretion. Stem-like and progenitor cells expressed the IL-6 receptor gp80 with concomitant expression of pSTAT3. Blockade of activated STAT3, by either anti-IL-6 antibody siltuximab (CNTO 328) or LLL12, a specific pSTAT3 inhibitor, suppressed the clonogenicity of the stem-like cells in patients with high-grade disease. In a murine xenograft model used to determine the in vivo effects of pSTAT3 suppression, LLL12 treatment effectively abolished outgrowth of a patient-derived castrate-resistant tumor. Our results indicate that the most primitive cells in prostate cancer require pSTAT3 for survival, rationalizing STAT3 as a therapeutic target to treat advanced prostate cancer.
Collapse
Affiliation(s)
- Paula Kroon
- Yorkshire Cancer Research Unit, Department of Biology, York
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin D, Chettiar S, Kitange G, Park IH, Sarkaria JN, Li C, Shakhparonov MI, Nakano I. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 2012; 19:631-42. [PMID: 23251006 DOI: 10.1158/1078-0432.ccr-12-0647] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PURPOSE Glioblastoma multiforme (GBM) is a devastating disease. Recent studies suggest that the stem cell properties of GBM contribute to the development of therapy resistance. EXPERIMENTAL DESIGN The expression of Survivin and Ran was evaluated by immunohistochemistry with GBM tissues, and quantitative reverse transcriptase (qRT)-PCR and immunocytochemistry with patient-derived GBM sphere cultures. With a computational structure-based drug design, 11 small-molecule compounds were designed, synthesized, and evaluated as inhibitor candidates for the molecular interaction of Survivin protein. The molecular mechanism of the lead compound, LLP-3, was determined by Western blot, ELISA, in situ proximity ligation assay, and immunocytochemistry. The effects of LLP-3 treatment on GSCs were evaluated both in vitro and in vivo. Quantitative immunohistochemistry was carried out to compare Survivin expression in tissues from 44 newly diagnosed and 31 recurrent post-chemoradiation GBM patients. Lastly, the sensitivities of temozolomide-resistant GBM spheres to LLP-3 were evaluated in vitro. RESULTS Survivin and Ran were strongly expressed in GBM tissues, particularly in the perivasculature, and also in patient-derived GSC cultures. LLP-3 treatment disrupted the Survivin-Ran protein complex in cancer cells and abolished the growth of patient-derived GBM spheres in vitro and in vivo. This inhibition was dependent on caspase activity and associated with p53 status of cells. Immunohistochemistry showed that Survivin expression is significantly increased in recurrent GBM compared with newly diagnosed tumors, and temozolomide-resistant GBM spheres exhibited high sensitivities to LLP-3 treatment. CONCLUSIONS Disruption of the Survivin-Ran complex by LLP-3 abolishes survival and growth of GSCs both in vitro and in vivo, indicating an attractive novel therapeutic approach for GBM.
Collapse
Affiliation(s)
- Hacer Guvenc
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Gandhi N, Wild A, Aziz K, Chettiar S, Gajula R, Zeng J, Herman J, Deweese T, Hales R, Tran P. Novel Hsp90 Inhibitor NVP-AUY922 Radiosensitizes Prostate Cancer Cells. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL. Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med 2012; 12:772-87. [PMID: 22292443 PMCID: PMC3412203 DOI: 10.2174/156652412800792589] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Revised: 11/10/2011] [Accepted: 12/20/2011] [Indexed: 12/12/2022]
Abstract
Prostate cancer is the most common cancer and second leading cause of cancer deaths among men in the United States. Most men have localized disease diagnosed following an elevated serum prostate specific antigen test for cancer screening purposes. Standard treatment options consist of surgery or definitive radiation therapy directed by clinical factors that are organized into risk stratification groups. Current clinical risk stratification systems are still insufficient to differentiate lethal from indolent disease. Similarly, a subset of men in poor risk groups need to be identified for more aggressive treatment and enrollment into clinical trials. Furthermore, these clinical tools are very limited in revealing information about the biologic pathways driving these different disease phenotypes and do not offer insights for novel treatments which are needed in men with poor-risk disease. We believe molecular biomarkers may serve to bridge these inadequacies of traditional clinical factors opening the door for personalized treatment approaches that would allow tailoring of treatment options to maximize therapeutic outcome. We review the current state of prognostic and predictive tissue-based molecular biomarkers which can be used to direct localized prostate cancer treatment decisions, specifically those implicated with definitive and salvage radiation therapy.
Collapse
Affiliation(s)
- P T Tran
- Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, 1550 Orleans Street, CRB2, RM 406, Baltimore, MD 21231, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Cooley JV, Chettiar S, Park IH, Bhasin D, Chakravarti A, Kai LP, Li C, Jacob NK. Abstract 3049: Development of novel survivin inhibitors to target mitotic machinery in cancers. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-3049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Survivin, a member of the inhibitor of apoptosis (IAP) protein family has essential roles in cell division and inhibition of apoptosis. Over-expression of survivin is observed in most human cancers, but survivin expression is not detectable in non-proliferating normal adult tissues. In dividing cells, survivin is detected as an integral component of the chromosomal passenger complex (CPC). In the CPC, survivin is organized as a homodimer, associated with Aurora B-kinase and plays a critical role in the recruitment of a number of proteins to the kinetochore and centromere, which are essential for mitotic progression. Several clinical correlative studies in cancer patients have shown that elevated levels of survivin decreases overall survival and leads to resistance to radiation and chemotherapeutic treatments. Thus, disruption of functional survivin along its dimer interface is hypothesized to inhibit the proliferation of cancer cells by further sensitizing them to therapeutic agents and radiation. Recently, through HTS-NMR and AS/MS affinity based screenings, compound 1 (C1) was identified to bind to the dimerization interface of survivin monomers. Further development of this compound was accomplished by computational modeling of inhibitor interactions along the dimerization interface, which has lead to the design of a panel of promising compounds analogous to compound 1. Two of the most potent inhibitors included LLP3 and LLP9, which showed significant levels of activity between 50 and 100 nM. In proliferating human umbilical vein endothelial cells (HUVEC) as well as in prostate cancer cells (PC3) cells, the compounds caused a delay in mitotic progression and major mitotic defects. These cells expressed physiological levels of GFP-tagged survivin, which were used for visualization in automated fluorescent time-lapse videomicroscopy to investigate how the survivin dimerization inhibitors affected cell cycle progression. The same microscopy methods were used for understanding the specificity and activity of each respective compound. The investigation of cells treated with each of the compounds allowed for resolution of subcellular level effects on mitotic progression and CPC organization/movement during mitosis. The qualitative microscopy data was enumerated in order to quantify effects the compounds had on cells. The cells were enumerated in triplicate and tracked for changes in their proliferation, cell death, changes in ploidy, and other mitotic defects. The relationships between structure and activity of the compounds will be discussed.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3049. doi:1538-7445.AM2012-3049
Collapse
Affiliation(s)
| | | | | | | | | | - Li Pui Kai
- 1The Ohio State University, Columbus, OH
| | | | | |
Collapse
|
14
|
Tran P, Hales R, Zeng J, Aziz K, Armour M, Aftab B, Chettiar S, Gajula R, Salih T, Rudin C, Gandhi N, Wong J. 34 HEDGEHOG PATHWAY INHIBITION AND RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70021-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|